We performed proof-of-concept in vivo experiments using orthotopic PDAC xenografts in mice and showed that neutralization EphB4-ephrinB2 interaction inhibited tumor growth and metastasis, suggesting that EphB4 is a relevant and druggable therapeutic target for this disease. The gene discussed is EPHB4; the disease is neoplasm.